<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24889748</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Expósito, Víctor</dc:author>
<dc:author>Seras, Miguel</dc:author>
<dc:author>Fernández-Fresnedo, Gema</dc:author>
<dc:description xml:lang="en">Atrial fibrillation is a common finding in patients with chronic kidney disease (CKD), which increases markedly the embolism risk. The CHADS2 and HAS-BLED scales, used in the general population to assess the risk/benefit of oral anticoagulation (OAC), underestimate respectively the risk of embolism and haemorrhage in CKD, making it difficult to decide whether to use OAC or not. Based on the available evidence, it seems indicated to use OAC in stage 3 CKD, while it is controversial in advanced stages. New OAC such as dabigatran and rivaroxaban have been approved in stage 3 CKD but their role is still somewhat uncertain.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Oral anticoagulation</dc:subject>
<dc:subject>Stroke</dc:subject>
<dc:subject>Atrial fibrillation</dc:subject>
<dc:subject>Hemodiálisis</dc:subject>
<dc:subject>Chronic kidney disease</dc:subject>
<dc:subject>Fibrilación auricular</dc:subject>
<dc:subject>Haemodialysis</dc:subject>
<dc:subject>Ictus</dc:subject>
<dc:subject>Anticoagulación oral</dc:subject>
<dc:subject>Enfermedad renal crónica</dc:subject>
<dc:date>2015 May 21 </dc:date>
<dc:title xml:lang="es">Anticoagulación oral en la enfermedad renal crónica con fibrilación auricular.</dc:title>
<dc:title xml:lang="en">[Oral anticoagulation in chronic kidney disease with atrial fibrillation].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
